微创与开放胰十二指肠切除术(LEOPARD-2):随机对照试验研究方案
LEOPARD-2是一项随机对照、平行组、患者盲法、多中心、2/3期优效性试验,计划纳入136例有症状的良性、癌前或恶性疾病患者,在加速康复条件下比较微创与开放胰十二指肠切除术,主要结局为功能恢复时间(天)。
要点
- 观察性研究提示MIPD在术中出血、术后并发症和住院时间方面优于开放手术且不增加总费用,但病例匹配研究未证实其优效性。
- 美国大型注册研究提示年MIPD量低于10例的中心行MIPD死亡率增加。
- LEOPARD-2假设即使在加速康复条件下,MIPD后功能恢复时间仍短于开放胰十二指肠切除术。
核心结论
- LEOPARD-2试验旨在评估在加速康复条件下,与开放胰十二指肠切除术相比,MIPD是否缩短功能恢复时间。
研究设计与样本
- 随机对照、平行组、患者盲法、多中心、2/3期优效性试验。
- 计划纳入136例有症状的良性、癌前或恶性疾病患者,随机分配至微创或开放胰十二指肠切除术,均在加速康复条件下进行。
- 入组中心须完成荷兰胰腺癌组LAELAPS-2(腹腔镜)或LAELAPS-3(机器人辅助)培训项目且已实施≥20例MIPD。
- 前40例(2期)后由数据安全监查委员会评估安全性结局(对治疗分配非盲)并决定是否继续至3期,2期患者纳入3期分析。
主要发现
- 观察性研究数据显示MIPD在术中出血、术后并发症和住院时间方面优于开放胰十二指肠切除术,且不增加总费用。
- 多个病例匹配研究未能证明MIPD的优效性。
- 美国大型注册研究提示年MIPD量低于10例的中心行MIPD死亡率增加。
关键数值与推荐
- 主要结局指标为功能恢复时间(天)。
- 次要结局指标包括手术和术后结局,含临床相关并发症、死亡率、生活质量和费用。
- 所有患者对手术方式设盲,至少至术后第5天,最好至功能恢复达成。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data from observational studies suggest that minimally invasive pancreatoduodenectomy (MIPD) is superior to open pancreatoduodenectomy regarding intraoperative blood loss, postoperative morbidity, and length of hospital stay, without increasing total costs. However, several case-matched studies failed to demonstrate superiority of MIPD, and large registry studies from the USA even suggested increased mortality for MIPDs performed in low-volume (<10 MIPDs annually) centers. Randomized controlled multicenter trials are lacking but clearly required. We hypothesize that time to functional recovery is shorter after MIPD compared with open pancreatoduodenectomy, even in an enhanced recovery setting. METHODS/DESIGN: LEOPARD-2 is a randomized controlled, parallel-group, patient-blinded, multicenter, phase 2/3, superiority trial in centers that completed the Dutch Pancreatic Cancer Group LAELAPS-2 training program for laparoscopic pancreatoduodenectomy or LAELAPS-3 training program for robot-assisted pancreatoduodenectomy and have performed ≥ 20 MIPDs. A total of 136 patients with symptomatic benign, premalignant, or malignant disease will be randomly assigned to undergo minimally invasive or open pancreatoduodenectomy in an enhanced recovery setting. After the first 40 patients (phase 2), the data safety monitoring board will assess safety outcomes (not blinded for treatment allocation) and decide on continuation to phase 3. Patients from phase 2 will then be included in phase 3. The primary outcome measure is time (days) to functional recovery. All patients will be blinded for the surgical approach, at least until postoperative day 5, but preferably until functional recovery has been attained. Secondary outcome measures are operative and postoperative outcomes, including clinically relevant complications, mortality, quality of life, and costs. DISCUSSION: The LEOPARD-2 trial is designed to assess whether MIPD reduces time to functional recovery, as compared with open pancreatoduodenectomy in an enhanced recovery setting. TRIAL REGISTRATION: Netherlands Trial Register, NTR5689 . Registered on 2 March 2016.
引用
- de Rooij T, van Hilst J, Bosscha K, et al. Minimally invasive versus open pancreatoduodenectomy (LEOPARD-2): study protocol for a randomized controlled trial. Trials. 2018. PMID: 29298706. doi:10.1186/s13063-017-2423-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。